The role of chemotherapy has become more and more important in the whole process of gastric cancer. S-1 or XELOX regimen is regarded as the standard treatment option in adjuvant chemotherapy. First-line chemotherapy in advanced gastric cancer has been established to improve survival, and the benefit from second-line chemotherapy is being acknowledged. More studies are needed to assess the neoadjuvant chemotherapy.
Antineoplastic Combined Chemotherapy Protocols ; administration & dosage ; therapeutic use ; Chemotherapy, Adjuvant ; Humans ; Stomach Neoplasms ; drug therapy

This is a report of ovarian carcinoma occurring in two sisters diagnosed almost at the same time, prompting prophylactic oophorectomy in a third sister. Histology of the overtly normal ovary in the third sister showed a focus of ovarian cancer. Discussion and a review of the literature suggest that any program designed to reduce the incidence of late-stage ovarian carcinoma should include the surveillance of family members of the index case, including the performance of prophylactic oophorectomy in the unaffected members of the family after they have completed their families.
Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Combined Modality Therapy ; Cystadenocarcinoma, Papillary - diagnosis

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Chemotherapy, Adjuvant ; Colorectal Neoplasms ; radiotherapy ; surgery ; therapy ; Combined Modality Therapy ; Humans

OBJECTIVE: To investigate the efficacy of high-risk myelodysplastic syndrome (MDS) patients treated by different doses of decitabine (DAC) and its safety. METHODS: Thirty patients with high-risk MDS were all treated by demethylation drug DAC. According to the doses of DAC, 30 patients were divided into 10-day regimen [6 mg/(m RESULTS: The patients were followed up to May 2020, in the 10-day regimen group, 10 cases achieved complete remission (CR), 3 cases achieved partial remission (PR), and 2 cases were progressive disease (PD). Four cases died, including 1 case for heart failure, 2 cases for respiratory failure and 1 case for serious infection. In the 5-day regimen group, 11 cases achieved CR, 1 case achieved PR, 3 cases were PD. Five cases died, including 2 cases for heart failure and 3 for serious infection. The CR rate and ORR of the patients in the two groups were 66.67% vs 73.33%, 86.67% vs 80.00%, respectively, which showed no significant differences, and the efficacy also showed no significant difference. After treatment, the levels of WBC, NE, Hb and PLT of the patients in 10-day regimen group were higher than those in 5-day regimen. In the 10-day regimen group, there were 11 cases of pneumonia, 2 cases of bacteremia, 1 case of skin infection and 1 case of urinary tract infection. While in the 5-day regimen group, 13 cases of pneumonia, 5 cases bacteremia, 1 case of skin infection and 3 cases of urinary tract infection. There were 2 cases with mild gastrointestinal response in the 10-day regimen group, and 7 cases with obvious nausea and anorexia in the 5-day regimen group. The symptoms were relieved after the treatment of acid suppression, stomach protection and antiemetic. The liver, kidney and heart function were monitored. One case liver function damage and 2 cases cardiac insufficiency were observed in the 10-day regimen group. Seven cases regimen cardiac insufficiency and 4 cases regimen liver function damage were observed in the 5-day regimen group. CONCLUSION 10-day regimen and 5-day regimen are equally effective, but 10-day regimen is less myelosuppressive and more safer, which can be applied in clinical.
Antineoplastic Combined Chemotherapy Protocols ; Azacitidine/therapeutic use* ; Cytarabine/therapeutic use* ; Decitabine/therapeutic use* ; Humans ; Myelodysplastic Syndromes/drug therapy* ; Treatment Outcome

Despite the reduced incidence and mortality, gastric cancer remains the second leading cause of cancer death in Korea. Metastatic gastric cancer is regarded as an incurable condition, and chemotherapy is usually accepted as standard palliation. A number of randomized studies were performed comparing supportive care strategies with intravenous chemotherapy. The results demonstrated that systemic treatment can actually improve overall survival and quality of life to a certain extent. However, there is no agreement for standard of treatment in this setting. Recently, a number of newer compounds such as taxanes, topoisomerase I inhibitors and oral fluoropyrimidines have been intensively studied. The surgical resection still remains as the cornerstone of gastric cancer treatment. However, the high rate of recurrence and poor survival after surgery provides a rationale for the early use of adjuvant treatment. A large intergroup study (INT-0116) showed that combined chemoradiation following to gastric resection improves median time to relapse and overall survival. Future advances in the therapy of advanced and resectable gastric cancers may come from the application of new cytotoxic and molecularly targeted agents such as growth factor receptor antagonists and anti-angiogenesis agents.
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; English Abstract ; Humans ; Palliative Care ; Stomach Neoplasms/*drug therapy

The incidence of cancer increases with age and most elderly patients will choose chemotherapy, and the complications of cytotoxic chemotherapy will be more common in these patients. Therefore, it is particularly important to predict the chemotherapy toxicity for the elderly patients. This review article summarizes the recent chemotherapy risk assessment tools for the elderly patients.
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Neoplasms ; drug therapy ; Risk Assessment

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Interferons ; Lymphoma, Mantle-Cell ; drug therapy ; Recurrence ; Thalidomide

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Humans ; Precursor Cell Lymphoblastic Leukemia-Lymphoma ; drug therapy

Acute myeloid leukemia (AML) has highly heterogeneous clinical manifestations and poor prognosis, and traditional chemotherapy is the main treatment. In recent years, with the in-depth development of next-generation sequencing technology, the treatment of AML is gradually exploring the precise targeted therapy in the direction of molecular biology and immunophenotype. The advent of various small-molecule inhibitors and immune-targeted drugs has brought hope to patients who cannot tolerate intensive chemotherapy or with relapsed/refractory AML. Compared with traditional chemotherapy, targeted therapy has the advantages of significant curative effect and fewer adverse effects. This article reviews the latest research progress of targeted drug therapy for AML.
Humans ; Leukemia, Myeloid, Acute/drug therapy* ; Immunotherapy ; Immunotherapy, Adoptive ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use*

Antineoplastic Combined Chemotherapy Protocols ; Bortezomib/therapeutic use* ; Dexamethasone ; Humans ; Multiple Myeloma/drug therapy* ; Treatment Outcome